Eisai wins Swedish reimbursement for epilepsy drug after two year court case
This article was originally published in Scrip
Executive Summary
Following a hard fought battle that lasted two years, Eisai has finally won reimbursement for its epilepsy drug Zebinix (eslicarbazepine acetate) in Sweden.